Jonas Schwestermann
The molecular landscape of proteasome inhibitor resistance of multiple myeloma in vivo
01.07.2020We here aim to dissect the molecular landscape of MM that is acquiring resistance to the most active PI, carfilzomib (CFZ) in vivo. We therefore here extend our model to orthotopic growth conditions of MM in murine bone marrow under continuous select...
Grundlagenforschung - 01.07.2020 - 31.12.2023
Automatisch geschlossen
Projektleitung: Driessen Christoph
Mitarbeiter/innen: Besse Andrej, Schwestermann Jonas, Kraus Marianne, Besse Lenka
The „seed and soil“-based pathogenesis of proteasome inhibitor resistance in multiple myeloma
01.01.2019Using the novel method of single-sell RNA sequencing, recently established by the Institute of Immunobiology at MFZ, KSSG, and our experience and knowledge about proteasome inhibitor resistance of myeloma plasma cells in vitro, we shall use the MFZ s...
Grundlagenforschung - 01.01.2019 - 31.12.2019
Automatisch geschlossen
Projektleitung: Besse Lenka
Mitarbeiter/innen: Besse Andrej, Schwestermann Jonas